Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KB15A is a non-hormonal contraceptive candidate developed by ZabBio Inc. It consists of an anti-sperm monoclonal antibody (KB15A.16.2) formulated into a polyvinyl-alcohol (PVA) based intravaginal film. The antibody is designed to target and agglutinate sperm cells within the vaginal environment, effectively trapping them in mucus and preventing them from reaching the egg for fertilization. This localized approach aims to provide an on-demand contraceptive option that avoids the systemic side effects associated with hormonal birth control. KB15A is currently being evaluated in Phase 1 clinical trials to assess its safety, mucosal pharmacokinetics, and local distribution following single and multiple dosing in healthy adult women.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on KB15A.